In April, the American Psychiatric Association (APA) released a comprehensive treatment guideline for treating adults who have been diagnosed with schizophrenia. Titled "The Practice Guideline for ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be ...

Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older 1 Approval follows a positive Committee for Medicinal Products ...

Windsor, United Kingdom/Valby, Denmark, 13 March 2025 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti ...

WINDSOR, England and VALBY, Denmark, March 13, 2025 /PRNewswire/ -- Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has ...